公开(公告)号：US11331269B2

公开(公告)日：2022-05-17

申请号：US16449100

申请日：2019-06-21

Applicant: Massachusetts Institute of Technology ,  The Broad Institute, Inc.

Inventor： Chengcheng Jin ,  Georgia Lagoudas ,  Paul Blainey ,  Tyler Jacks

IPC: A61K45/00 ,  A61K9/00 ,  A61P35/00 ,  C07K16/24 ,  C07K16/28 ,  A61K31/43 ,  A61K31/7036 ,  A61K31/4164 ,  A61K38/08 ,  A61K31/7052 ,  A61K31/7048 ,  A61K31/7056 ,  A61K45/06

Abstract: It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.

公开(公告)号：US20220105120A1

公开(公告)日：2022-04-07

申请号：US17426669

申请日：2020-02-05

Applicant: Clear Creek Bio, Inc.

Inventor： Vikram S. Kumar ,  David P. Hesson

IPC: A61K31/7056 ,  A61K31/343 ,  A61K31/41 ,  A61K31/427 ,  A61K31/519 ,  A61K31/444 ,  A61K31/6615 ,  A61K31/7004

Abstract: The invention provides compositions and methods for treating conditions in a subject by inhibiting inosine monophosphate dehydrogenase. The invention provides compositions and methods that provide periods of sustained inhibition of inosine monophosphate dehydrogenase followed by periods in which enzyme activity is not inhibited. The invention also provides methods that include monitoring inhibition of inosine monophosphate dehydrogenase via analysis of GTP levels.

公开(公告)号：US11246880B2

公开(公告)日：2022-02-15

申请号：US15535019

申请日：2015-12-18

Applicant: Arizona Board of Regents on Behalf of The University of Arizona

Inventor： Andrew P. Capaldi ,  James E. Hughes Hallett

IPC: A61K39/395 ,  A61K31/7056 ,  A61K31/155 ,  A61K31/60 ,  A61K45/06 ,  C07K16/18

Abstract: Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or other agents, and said agents may be used to treat or prevent a disease or condition associated with the fungi and parasite. The agent may target Kog1 of TORC1, e.g., the agent may directly or indirectly inhibit Kog1 leading to aggregation of the TORC1 complex.

公开(公告)号：US11219631B2

公开(公告)日：2022-01-11

申请号：US16108799

申请日：2018-08-22

Applicant: Foamix Pharmaceuticals Ltd.

Inventor： Dov Tamarkin ,  Enbal Ziv ,  Yohan Hazot ,  David Schuz

IPC: A61K31/7056 ,  A01N25/16 ,  A61K9/12 ,  A61K47/10 ,  A61K47/38 ,  A61K31/196 ,  A61K31/327 ,  A61K31/573 ,  A61K31/58 ,  A61K9/00

Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.

公开(公告)号：US11208411B2

公开(公告)日：2021-12-28

申请号：US16085981

申请日：2017-03-17

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  Washington University

Inventor： Florentine Rutaganira ,  Kevan M. Shokat ,  Laurence David Sibley ,  James W. Janetka

IPC: C07D487/04 ,  A61P33/02 ,  A61K31/42 ,  A61K31/505 ,  A61K31/7056

Abstract: Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases.

公开(公告)号：US20210395731A1

公开(公告)日：2021-12-23

申请号：US16906019

申请日：2020-06-19

Applicant: City University of Hong Kong

Inventor： Chi Kong Terrence Lau ,  Oi Kwan Law

IPC: C12N15/113 ,  A61P31/04 ,  A61K31/7088 ,  A61K31/43 ,  A61K31/546 ,  A61K31/165 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/4709 ,  A61K31/5377 ,  C12N7/00 ,  A61K9/51

Abstract: A method of inhibiting growth of a bacterium including steps of: a) delivering a polynucleotide including a sequence of SEQ ID NO: 1 or a homologue thereof to the bacterium, and b) contacting the bacterium with an effective amount of an antibiotic; wherein the bacterium is Pseudomonas aeruginosa. A method of treating a subject suffering from an infection caused by a bacterium which is Pseudomonas aeruginosa and the method including steps of: i) delivering said polynucleotide to a tissue infected by the bacterium or a bacterial cell in the subject; and ii) administering an effective amount of an antibiotic to the subject. A composition and a recombinant plasmid containing said polynucleotide.

公开(公告)号：US20210369913A1

公开(公告)日：2021-12-02

申请号：US17057924

申请日：2020-11-06

Applicant: GCS Co., Ltd.

Inventor： Chang Sik KIM

IPC: A61L27/26 ,  A61K9/50 ,  A61K31/167 ,  A61K31/445 ,  A61K31/431 ,  A61K31/7036 ,  A61K31/7056 ,  A61K31/4178 ,  A61K31/5383 ,  A61K31/496 ,  A61K31/665 ,  A61L27/54 ,  A61L27/58

Abstract: Disclosed are a sustained-release injection formulation containing a biodegradable polymer double microcapsule that contains a conjugate of poly-L-lactic acid (hereinafter referred to as “PLLA”) filler and hyaluronic acid (hereinafter referred to as “HA”) and is capable of controlling the release rate of PLLA, and a method of preparing the same.

公开(公告)号：US20210353660A1

公开(公告)日：2021-11-18

申请号：US17282526

申请日：2019-10-04

Applicant: Octagon Therapeutics Inc.

Inventor： Nathaniel Sherden

IPC: A61K31/7056

Abstract: The present disclosure provides inosine-5′-monophosphate dehydrogenase (IMPDH)-inhibiting nucleoside derivatives having anti-infective activities, and methods of their synthesis and use.

公开(公告)号：US20210322462A1

公开(公告)日：2021-10-21

申请号：US17234656

申请日：2021-04-19

Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Dianne K. NEWMAN ,  Melanie A. SPERO ,  Manuela MARTINS-GREEN ,  John D. COATES

IPC: A61K33/00 ,  A61K31/43 ,  A61K31/424 ,  A61K31/7056 ,  A61K31/545 ,  A61K31/496 ,  A61K31/4164 ,  A61K31/7036 ,  A61K31/431 ,  A61K31/546 ,  A61K31/427 ,  A61K33/14 ,  A61K33/18 ,  A61K38/48 ,  A61K38/18 ,  A61K31/355 ,  A61K31/198 ,  A61K9/06 ,  A61K9/00 ,  A61P31/02 ,  A61P17/02

Abstract: Wound healing matrices, compounds, compositions, methods and systems comprising one or more chlorates, one or more chlorites, one or more antibiotics, one or more other antimicrobials, and/or one or more wound healing agents.

公开(公告)号：US20210322324A1

公开(公告)日：2021-10-21

申请号：US17267656

申请日：2019-08-14

Applicant: AVOLYNT

Inventor： William Owen WILKISON ,  James Trinca GREEN

IPC: A61K9/28 ,  A61K31/7056 ,  A61P1/16

Abstract: The invention relates to the use of pharmaceutical compositions of the SGLT2 inhibitor, remogliflozin etabonate, to treat primary sclerosing cholangitis (PSC). Methods and compositions associated with the invention can improve or maintain clinical outcomes of PSC symptoms, such as ascites accumulation, hepatic encephalopathy, development of varices, jaundice, variceal bleeding, cholangiocarcinoma, hepatocellular carcinoma, evidence of cirrhosis, and colorectal cancer.